<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025298</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-24981</org_study_id>
    <secondary_id>EORTC-24981</secondary_id>
    <nct_id>NCT00025298</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx</brief_title>
  <official_title>A Feasibility Study Of Primary Chemotherapy Followed By Concomitant Chemoradiation With And Without Amifostine In Patients With Locally Advanced Undifferentiated Nasopharyngeal Cancer (UNPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Combining radiation therapy with chemotherapy may kill more tumor cells. Giving&#xD;
      chemoprotective drugs such as amifostine may protect normal cells from the side effects of&#xD;
      chemotherapy and radiation therapy.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of paclitaxel and carboplatin&#xD;
      followed by cisplatin plus radiation therapy with or without amifostine in treating patients&#xD;
      who have locally advanced cancer of the nasopharynx.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the overall incidence of grade 3 or 4 mucositis in patients with locally&#xD;
           advanced undifferentiated nasopharyngeal cancer treated with paclitaxel and carboplatin&#xD;
           followed by cisplatin and radiotherapy with or without amifostine.&#xD;
&#xD;
        -  Compare the feasibility and activity of these regimens in these patients.&#xD;
&#xD;
        -  Determine the toxicity of paclitaxel and carboplatin in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to WHO&#xD;
      performance status (0 vs 1 vs 2), response to induction chemotherapy (complete vs partial vs&#xD;
      stable disease vs not evaluable), and participating center.&#xD;
&#xD;
      Patients receive induction chemotherapy comprising paclitaxel IV over 3 hours and carboplatin&#xD;
      IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with a complete or partial response after 2 courses of induction chemotherapy&#xD;
      receive 2 additional courses before randomization. Patients with stable disease after 2&#xD;
      courses of induction chemotherapy or who cannot be evaluated after 1 course proceed directly&#xD;
      to randomization. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive cisplatin IV on days 1, 22, and 43. Patients also undergo&#xD;
           radiotherapy daily 5 days a week for 6.5 weeks.&#xD;
&#xD;
        -  Arm II:Patients receive amifostine subcutaneously daily. Patients receive chemotherapy&#xD;
           and radiotherapy as in arm I.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 41-93 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>July 2001</start_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">5</enrollment>
  <condition>Drug/Agent Toxicity by Tissue/Organ</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Oral Complications</condition>
  <condition>Radiation Toxicity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amifostine trihydrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed undifferentiated nasopharyngeal cancer (UNPC)&#xD;
&#xD;
               -  Locoregionally advanced disease&#xD;
&#xD;
                    -  T2b, N1 (greater than 3 cm) or N2&#xD;
&#xD;
                    -  T3, N1 (greater than 3 cm) or N2&#xD;
&#xD;
                    -  T4, N1 (greater than 3 cm) or N2&#xD;
&#xD;
                    -  Any T, N3&#xD;
&#xD;
               -  No squamous cell histology&#xD;
&#xD;
          -  At least 1 unidimensionally measurable target lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
          -  No evidence of distant metastases&#xD;
&#xD;
          -  No signs or symptoms of CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  15 to 70&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 150,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 12 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 70 mL/min&#xD;
&#xD;
          -  Calcium normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No hypotension or hypertension requiring therapy&#xD;
&#xD;
          -  No prior myocardial infraction&#xD;
&#xD;
          -  No pre-existing uncontrolled cardiac disease&#xD;
&#xD;
          -  No signs of cardiac failure&#xD;
&#xD;
          -  No rhythm disturbances requiring medication&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No sensory neuropathy grade 2 or greater unless due to cranial nerve&#xD;
&#xD;
          -  No uncontrolled infections&#xD;
&#xD;
          -  No sensitivity to aminothiol compounds&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately controlled carcinoma in&#xD;
             situ of the cervix or basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for UNPC&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy except corticosteroids for antiemetic prophylaxis&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy for UNPC&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior surgery for UNPC except cervical lymphadenectomy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 1 month since prior investigational agent&#xD;
&#xD;
          -  No other concurrent anticancer drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Licitra, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genoa (Genova)</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Milano (Milan)</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Jerez</name>
      <address>
        <city>Jerez</city>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University-Institute of Oncology</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Oncology Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II nasopharyngeal cancer</keyword>
  <keyword>stage III nasopharyngeal cancer</keyword>
  <keyword>stage IV nasopharyngeal cancer</keyword>
  <keyword>oral complications</keyword>
  <keyword>drug/agent toxicity by tissue/organ</keyword>
  <keyword>radiation toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

